Highly selective inhibitors of HDAC6 for the treatment of cancers and neurodegenerative disease
Researchers in RCSI and the Dana-Farber Cancer Institute have discovered a novel structural class of highly-selective HDAC6 inhibitors. These patented small molecules have a unique non-hydroxamic acid chemical structure and are >250-fold selective over the other HDACs. The lead compound BAS-2 has been shown to inhibit glycolysis in Triple Negative Breast Cancer Cells – a unique vulnerability independent of the mitochondrial apoptosis pathway which is one of the key drivers of chemoresistance.
ChemoGel: A thermoresponsive drug delivery platform for intratumoral delivery of chemotherapeutics in pancreatic cancer
ChemoGel is a unique, thermoresponsive, hydrogel drug delivery platform for the site-specific delivery and sustained release of chemotherapeutics at solid tumour sites. ChemoGel is a platform technology which enables the sustained local delivery of chemotherapeutics agents and is intended for use in the chemical ablation of solid tumours alone or in conjunction with other treatment approaches. The technology is now in pre-clinical development at RCSI for its first clinical indication in pancreatic cancer.
ADAM22 and LGI1 mimetic peptide: A complete solution as a directed therapeutic strategy for endocrine related tumour metastasis
ADAM22 is a novel therapeutic target for metastatic disease, with a peptide drug based on its natural ligand, LGI1. The technology compromises of a clinically validated and commercially ready immunohistochemical assay for the detection of ADAM22 in breast cancer tissue to be utilised as (i) as a biomarker for predicting the metastatic potential of breast tumours in endocrine treated breast cancer patients and (ii) as a companion diagnostic for a novel therapeutic (LGI1) to treat metastatic ER positive breast cancer.
Rapid Acting Pharmaceutical for Infectious Disease (RAPID)
A key hallmark of sepsis is loss of epithelial and endothelial barrier integrity thus facilitating fluid to leak into tissues that results in organ failure, shock and death. To date, dysfunction of the endothelial/epithelial barrier has been untreatable. Inthelia Therapeutics is developing a novel small molecule drug, cilengitide, that stabilises the epithelial and endothelial barrier. Inthelia has granted patents to protect use of cilengitide in sepsis and others filed for COVID-19..
STARMAT – A versatile star polypeptide platform for oligonucleotide drug delivery
Star-polymers are a new class of polymer architecture which consist of linear arms radiating from a central core. Novel star polypeptide-based vectors discovered at RCSI have superior transfection and delivery efficacy compared to current commercially available technologies coupled with improved stability, biocompatibility and immunogenicity. Therapeutic applications include the targeted delivery of DNA plasmids, siRNA mRNA and miRNA and incorporation into bioactive scaffolds and medical devices.
FKBPL: Novel target for obesity and metabolic syndrome
The obesity pharmaceutical market is projected to grow from $407 million in 2012 to $8.4 billion by 2022. 40-70% of inter-individual variability in BMI is attributable to genetic factors. Although treatment strategies are available, the side-effects associated with their use necessitates development of novel therapies. FKBPL is a promising novel drug target for obesity and metabolic syndrome and researchers at RCSI have developed FKBPL peptide mimetics and gene therapies as therapeutic options.
A novel therapeutic approach to restore haemostasis in individuals with haemophilia
RCSI has developed a novel therapeutic approach to restore haemostasis in individuals with haemophilia by the inhibition of the initiation and activity of anticoagulant pathways mediated by activated protein C (APC).
Modulating macrophage plasticity for the treatment of disease
Researchers in RCSI have discovered that enhancing the expression of a particular enzyme maintains macrophages in an anti-inflammatory and tissue regenerative state. They have developed a target site blocker which up-regulates the expression of this enzyme and can be incorporated within biocompatible nanoparticles for targeted drug delivery. This disruptive technology can be exploited as a therapy for a range of autoimmune, inflammatory and neurological diseases associated with an inflammatory burden mediated by macrophages.
Novel RNA therapeutic targeting sodium channelopathies
Genetic epilepsies caused by mutations to voltage-gated sodium channels do not currently have adequate treatment options. These diseases begin in the early years of life, with infants suffering severe seizures as well as developmental deficits such as ASD. RCSI researchers are developing a new and innovative treatment which selectively restores the function of specific voltage-gated sodium channel genes.
Novel NIR dyes for the endogenous labelling of exosomes
The recognition of the biological, diagnostic and medical importance of exosomes has given rise to an urgent need for efficient labelling of these extracellular vesicles in ways that do not alter their inherent characteristics. RCSI scientists have developed a simple and efficient endogenous method of labelling exosomes with a novel NIR dye without the need for tedious immunolabelling or synthetic or chromatographic manipulations.